Blood Cancer
Data presented on Revimid in malignant blood disorders
Published in Blood Weekly, December 11th, 2003
These are malignant disorders of blood cell production that eventually lead to acute leukemia and affect approximately 300,000 people worldwide. Revimid has received fast track designation from the U.S. Food and Drug Administration (FDA) for the treatment of MDS and for multiple myeloma, a bone marrow cancer that results in more than 14,000 new cases each year.
"Preliminary results of the study show that Revimid may increase the growth of red blood cells (erythropoiesis) and demonstrate...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2003-12-11)
More Articles from Blood Weekly
- Stem-Cell Research
Endoglin-based method enables purification of long-term repopulating HSCs - Leukemia Therapy
In AML patients, pretransplant MRD status predicts auto-SCT outcome - Leukemia Therapy
Stem cell mobilization feasible with rHu-G-CSF alone for CML patients in IM-induced CCR - Stem-Cell Research
IL-7 receptor expression determines lymphoid cell fate - Stem-Cell Transplantation
Low-dose cidofovir effective against post-SCT adenovirus infection - AIDS Epidemiology
China's AIDS epidemic is reaching "frightening" levels, renowned expert says - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
